The dominant rationale to generate new (and to assess old) anticancer chemotherapeutic agents is to determine their cell-autonomous effects — that is, their capacity to reduce the growth (cytostasis) ...

Investor Relations communicates with investors, financial analysts and rating agencies and strives to achieve a consistently fair valuation for UBS shares through best-in-class disclosure, ...